Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  sapanisertib
Find trials that include:  Any drugs shown
Results 1-17 of 17 for your search:
Start Over
Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C31001, NCI-2014-00386, NCT02049957
Sapanisertib in Treating Patients with Newly Diagnosed or Refractory/Metastatic Anaplastic Thyroid Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-223, NCI-2015-01607, NCT02244463
Sapanisertib or Pazopanib Hydrochloride in Treating Patients with Locally Advanced or Metastatic Sarcoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091304, NCI-2015-01929, NCT02601209
Sapanisertib in Treating Patients with Recurrent or Metastatic Merkel Cell Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-223, NCI-2016-00695, NCT02514824
TORC1/2 Inhibitor MLN0128 in Treating Patients with Stage IV or Recurrent Lung Cancer
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9780, NCI-2015-00545, 2015-00500, NCT02417701
TORC1/2 Inhibitor INK128 in Treating Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1482, NCI-2015-01000, 9775, NCT02484430
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: C31005, NCI-2016-00540, U1111-1172-1808, 2015-002133-22, NCT02724020
Sapanisertib in Treating Patients with Relapsed Lymphoma
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0501, NCI-2016-00671, NCT02727777
Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: C31004, NCI-2016-00972, 2014-005394-37, U1111-1168-1824, NCT02725268
Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C32001, NCI-2014-01567, 2013-000466-11, NCT01899053
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients with Recurrent Glioblastoma or Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-079, NCI-2014-01118, 9552, NCT02142803
Sapanisertib and Ziv-Aflibercept in Treating Patients with Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0665, NCI-2014-01107, 9585, NCT02159989
A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Patients With Advanced Nonhematologic Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C28002, NCI-2015-01108, 2014-003340-12, NCT02327169
TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients with Advanced EGFR Mutation Positive Non-small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PJC-020, NCI-2015-01139, 9910/PJC-020, 9910, NCT02503722
Sapanisertib and Alisertib in Treating Patients with Incurable Refractory Solid Tumors or Metastatic Triple-Negative Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 15-1135, NCI-2016-00443, NCT02719691
Alisertib and Sapanisertib in Treating Patients with Locally Advanced or Metastatic HPV-Associated Cancer
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2015-0689, NCI-2016-01190, NCT02812056
TORC1/2 Inhibitor INK128 before and after Surgery in Treating Patients with Recurrent Glioblastoma
Status: Temporarily closed
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ABTC-1301, NCI-2014-00907, 1301, NCT02133183
Start Over